



“Adding Health to Life...”



DEVA,\* was established in

**1958**

by **27** shareholders.



\*an acronym for Doktor, Eczacı ve Aletleri (Physicians, Pharmacists and Diagnostics)

We are a long-standing pharmaceutical manufacturer in Turkey with

~**2500**

employees working for a healthier future in our **EU GMP-certified & US FDA** approved manufacturing facilities and our R&D center.



We manufacture finished products and API's in our facilities at

**3**

different locations in Çerkezköy and Kartepe with an annual capacity of

**578,000** units



We have over **800** marketing authorizations

in more than **60** countries and export to **50** countries.



Our portfolio includes

~**600**

products in **13** therapeutic areas



DEVA was selected as the Best R&D Company by the Turkish Ministry of Science, Technology and Industry and as the Best R&D Company by Eczacı Magazine in 2013, 2015 and 2017.



In **2018**

Turkey's **largest pharmaceutical logistics center**, started its operations with 32000 pallet capacity.



In **2020**

we allocated ~**7%** of our sales into R&D.



## We Work to Add Health to Life

Active since 1958, DEVA Holding has concentrated its efforts on increasing human health and quality of life.

Our target is to serve the medical world by providing means of treatment with an innovative approach and to become a respectable and preferred brand of global scale with our reliable products.

To this end we are making investments while developing and offering accessible, innovative and high-quality products for a healthier future...





## History 1950



- 1958** DEVA was founded by 27 shareholders with a capital of 500.000 TL.
- 1960** The first DEVA manufacturing plant was opened in Beyoğlu, Tünel.
- 1961** DEVA Holding's capital was raised to 10 million TL and its shareholders reached 1500 people.
- 1963** The DEVA Bomonti Pharmaceutical Plant was opened.
- 1968** The DEVA Ampul Plant was opened in İzmit.
- 1970** Turkey's first drug raw material production was carried out by DEVA Holding with the production of Tetracycline and Oxytetracycline.
- 1973** The first large production plant was purchased from the Italian Farmitalia.
- 1978** The Carlo Erba Pharmaceutical Plant was purchased.
- 1981** With the production of Gentamicin, DEVA Holding A.Ş. took its place among the 5 companies in the world that are capable of producing this active agent.
- 1983** A detergent and cologne plant belonging to DEVA Holding was opened in İzmit.

- 1986** DEVA Holding A.Ş.'s stock certificates started to be traded at the Istanbul Stock Exchange (İMKB).
- 1988** The production of Lincomycin started at the drug active agent production plants.
- 1991** The synthesis plant was founded and the production of Cefuroxime Axetil started.
- 1994** With the production of Potassium Clavulanate, DEVA Holding A.Ş. took its place among the 4 companies in the world that are capable of producing this active agent.
- 2002** The Holding administrative building in Levent was completed.
- 2006** The majority interest of DEVA Holding was transferred to EastPharma.
- 2007** The company headquarters moved to the new office in Halkalı. The construction of the Çerkezköy and İzmit Köseköy plants started.

- 2008** The licence and franchises of 18 Roche products were taken over. The company's 50 years of success in the industry was celebrated throughout Turkey together with physicians and chemists.
- 2009** "DEVARGE", the R&D Centre, was founded.
- 2010** The licence and sale rights of 10 products were purchased from Bristol-Myers Squibb.
- 2011** Zentiva's API production plant in Çerkezköy was acquired.
- 2012** European GMP (Good Manufacturing Practice) certification was obtained from the German Ministry of Health.
- 2013** DEVA was deemed worthy of the first prize in the "R&D Study of the Year" branch of the Golden Mortar competition. All production sites were concentrated at the Çerkezköy and Kartepe plants.
- 2014** The inhaler drug production plant built on a 1700 m<sup>2</sup> land in Çerkezköy was opened. The ophthalmology production line was established in the Kartepe production plant. The first equivalent product to be used in the treatment of dry eye was offered to serve Turkish medicine.

- 2015** Ministry of Science, Industry and Technology named DEVA as having the best R&D Center in the pharmaceutical industry. DEVA received Eczacı Magazine's Golden Mortar Award, recognizing successful organizations and companies in the pharmaceutical sector, for having the best R&D center of the year.
- 2016** DEVA manufacturing plants received FDA approval. DEVA gained foothold in Germany with Devatis.
- 2017** First finished product exportation to USA. DEVA manufacturing site received FDA approval.
- 2018** DEVA logistics center, Turkey's largest logistics center, started its operations. Tamoxifen, the golden standard in breast cancer treatment, has been produced locally in Turkey for the first time. DEVA R&D center has been recognized by the best R&D center by Eczacı Magazine.
- 2019** The first pharmaceutical export to Switzerland started. The license approvals reached 700 in more than 60 countries.
- 2020** The license approvals reached more than 800 in over 60 countries.



We have been serving health since 1958 as one of our country's deep-rooted pharmaceutical producers with approximately **2500** employees, **3** production sites and our R&D centre.

## We Are One of Turkey's Deep-Rooted Pharmaceuticals Producers

### **Human Medicine:**

Our portfolio includes around **600** products in **13** different therapeutic areas from oncology to cardiology and from the respiratory system to the nervous system.

### **Drug Raw Material Production:**

We carry out the production and export of raw materials in order to meet the demand of the pharmaceuticals industry.

### **Veterinary Drugs:**

With VETAŞ, we have become a company with a product range that is one of the widest in the sector.

### **Medical Ampoule Production:**

We meet a significant part of the market's demand as one of the leading companies in the production of medical ampoules.

**We have been serving our country for over 60 years.**





**Our aim is to become a leader in the development of generic drugs...**

Within the scope of R&D work, we are developing innovative new forms and products of high added value with our laboratories and production sites equipped with state-of-the-art technology. In keeping with this, in 2020 we allocated approximately 7% of our turnover to R&D.

Consisting of the pre-formulation and pilot production area, synthesis and scale-up laboratories, stability area, analytical development laboratories, biotechnology laboratories, oncolytic and hormone production area, pilot production area, weighing area, raw material packaging material, finished product storehouse, analysis laboratories and CMC documentation archives, R&D facilities covers an area of 7.000 m<sup>2</sup>.

## R&D Focus and Approvals

We conduct our R&D activities in keeping with all ethical and legal regulations to prove the safety, effectiveness and quality of the product in order to increase the product's accessibility, to develop methods to increase efficiency for sustainable growth and to optimise production.

Our work ethics involve ensuring that the quality of our products always meet current standards as well as finding new formulations, dosage forms, different synthesis methods and new polymorph methods.

Our target is to ensure vertical integration in strategic products as a pioneer in the development of generic drugs, to become a world-class player in developing active agents and new polymorphs, to create difference by developing value-added products, to continue developing products for regulated markets (EMA and FDA), to invest in the future by adapting new technologies to our company, to develop products with a high added value by ensuring university-industry cooperation and to ensure the protection of our intellectual property rights through patent registration.



DEVA Holding production facilities are located in three different locations in Çerkezköy and Kartepe, and they are established on an area of 216.409 m<sup>2</sup>, 90.204 m<sup>2</sup> of which consists of covered area. DEVA Holding offers innovative and different products with a quality experience to ensure that a healthy life is accessible to all at a global level and paves the way to be the first choice by creating leading pharmaceuticals brands in the therapeutic areas in which it competes.

With its independent production sites, its laboratories equipped with state-of-the-art technology and its strong team, DEVA Holding is a local company that carries out the most comprehensive production in Turkey. Thanks to its new facilities, it has achieved an annual production capacity of 578 million units.

## DEVA, Aims to Become a Global Company

With all machinery in the solid oncology section equipped with insulators to prevent any possible damage that may arise from the personnel's contact with the product. DEVA Holding is the first pharmaceutical company in Turkey that employs a completely closed system for manufacturing oncology products.

All production facilities are awarded OHSAS 18001 certificates with respect to occupational health and safety, and ISO 14001 certificates with respect to environment-friendly practices.

In the modern buildings equipped with technological equipment approved by national and international authorities;

### **Çerkezköy-I Production Site;**

Liquid / semi solid, solid, betalactam 1, betalactam 2, cephalosporin, penisilin, inhaled products MDI and hormon products.

### **Çerkezköy-II Production Site;**

Solid oncology, liquid oncology, animal health products and API

### **Kartepe Production Site;**

Sterile injectable products in ampoule, liquid vial and lyophilized vial forms and SVP products manufactured on lines using BFS technology.

Empty medical ampoules, used for manufacturing ampoule forms, are also manufactured at this site.

### **DEVA Logistic Center;**

Turkey's largest pharmaceuticals logistics center with 3200 pallet capacity and equipped with latest technology.








DEVA production plants offer all therapeutic presentation forms in non-sterile fields. Production is carried out through many different technologies in sterile forms.

### Non-sterile

- Tablets
- Coated tablets
- Enteric-Coated Tablets
- Capsules
- Micropellet Capsules
- Sugar Coated Pills
- Syrups
- Suspensions
- Creams
- Pomades
- Ointments
- Drops
- Sprays
- Gels
- Suppositories
- MDI (metered dose inhaler)
- DPI (dry powder inhaler)

### Sterile

- Ampoules
- Vials
- Lyophilisation
- BFS SVP
- Eye Drop
- Nebul
- Sterile Raw Material
- Sterile Animal Health



DEVA's quality is based on the principles of diligence and innovation.

The DEVA's quality culture rests on the concept of "correct result at the first try." All of our employees adopt this principle with respect to patient safety and to ensure perfection in all operations.

The DEVA's quality culture starts with product research and development and covers all phases from production to the distribution network.

#### **The Quality System**

Our quality management system provides consistency throughout all of our production facilities as well as an operational procedure framework that ensures production under the best practices. This system also meets legal requirements and the international Good Manufacturing Practices (GMP) standards. The quality management system includes risk management techniques and pragmatic implementations.

## Quality Culture & Quality System







## Our Therapeutic Areas







**Sustaining regional expansion, we are on our way to becoming a global company.**

Our regional growth operations and export activities are increasing. We have more than **800** licenses in over **60** countries including Switzerland, Germany, the Netherlands and the UK. We export drugs and drug raw materials to more than **50** countries.

Within the scope of our international operations, depending on business models

- **Distributorship**
- **Out-licensing and Supply**
- **In-licensing**
- **API Export**
- **Contract Manufacturing**
- **Co-Development**

processes continue.

## We are Growing in International Markets








Our division VETAŞ is making efforts to offer veterinarians a wide product range with more than 140 products based on form in 7 different therapeutic fields.

VETAŞ is among the leaders in animal health since 1973. We offer veterinarians accessible, innovative and high-quality products thanks to our R&D team for animal health. We continue our activities keenly with our experienced team mostly consisting of veterinarians, which follow, research and provide solutions to the problems and needs of our country's livestock industry.



DEVA officially supports Turk Kizilay.

We are aware of the value and importance of the work we carry out for the lives to which we add health. For a healthier future and sustainable development, we see social responsibility activities as an integral part of our operations.

Within this scope, we focus our social responsibility activities especially on education, public health and the environment.

## Our Social Responsibility Understanding

- We donate drugs according to need in cooperation with public corporations and non-governmental organisations.

**Each life to which we add health lends us strength to do even better...**



**Adding Health to Life...**

Please contact our company for further information.  
DEVA HOLDING A.S. Halkalı Merkez Mah. Basın Ekspres Cad. No:1 34303 Kucukcekmece - ISTANBUL / TURKEY Tel: +90 212 692 92 92

 [www.deva.com.tr/en](http://www.deva.com.tr/en)

 [export@deva.com.tr](mailto:export@deva.com.tr)



DEVA/ASB/DA/14